IO BiotechIOBT
IOBT
About: IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Employees: 79
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
15% more capital invested
Capital invested by funds: $18.1M [Q4 2024] → $20.8M (+$2.67M) [Q1 2025]
0.95% less ownership
Funds ownership: 29.89% [Q4 2024] → 28.94% (-0.95%) [Q1 2025]
19% less funds holding
Funds holding: 26 [Q4 2024] → 21 (-5) [Q1 2025]
63% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 8
83% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$12
789%
upside
Avg. target
$12
789%
upside
High target
$12
789%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Emily Bodnar | 789%upside $12 | Buy Reiterated | 1 Apr 2025 |
Financial journalist opinion
Positive
Zacks Investment Research
2 weeks ago
IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy?
After reaching an important support level, IO Biotech, Inc. (IOBT) could be a good stock pick from a technical perspective. IOBT recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Neutral
GlobeNewsWire
3 weeks ago
IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, announced today that Mai-Britt Zocca, PhD, the company's President and CEO, along with Amy Sullivan, the company's CFO, and Qasim Ahmad, MD, the company's CMO, will be participating in a fireside chat at the TD Cowen 6th Annual Oncology Summit: Insights for ASCO & EHA being held virtually May 27-28, 2025. Additionally, Dr. Zocca will be presenting and Dr. Zocca, Amy Sullivan, and Dr. Ahmad will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 3-5, 2025 in New York, NY.
Neutral
GlobeNewsWire
1 month ago
IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights
Primary endpoint of pivotal Phase 3 trial (IOB-013/KN-D18) of lead investigational therapeutic cancer vaccine in patients with advanced melanoma still expected to readout in third quarter of 2025 Data presented at recent congresses reinforces the potential of the company's T-Win candidates to reshape the tumor microenvironment and drive more effective anti-tumor responses Company recognized as one of the most innovative biotechnology companies in the world by Fast Company Company to participate in TD Cowen's 6th Annual Oncology Innovation Summit on May 27 and Jefferies Global Healthcare Conference on June 4, 2025 NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today reported financial results and business highlights for the first quarter of 2025. The company continues to advance its pipeline, presenting new data further defining the mechanism of action for its T-Win therapeutic cancer vaccines, and reaffirming its expectation that the Phase 3 pivotal trial will readout in the third quarter of 2025.
Neutral
GlobeNewsWire
1 month ago
IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
NEW YORK, April 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that one of its scientific co-founders, Mads Hald Andersen, DMSc, PhD, Director of the National Center for Cancer Immune Therapy (CCIT-DK), chaired and presented at an educational session on cancer vaccines at the 2025 American Association for Cancer Research (AACR) Annual Meeting. The session brought together leading oncology scientists and explored the latest advancements in cancer vaccine research, from preclinical innovation to clinical implementation, providing perspective on the future of cancer vaccines and their potential to reshape cancer immunotherapy (session #ED59).
Neutral
GlobeNewsWire
1 month ago
IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170
Preclinical data further support the potential of dual-antigen and TGF-β-directed vaccines to reshape the tumor microenvironment and drive anti-tumor immunity NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced the presentation of new preclinical data for two vaccine candidates developed based on its T-win® platform at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, Illinois. One poster presentation provides further insights on the mode of action of IO102-IO103, the company's lead investigational therapeutic cancer vaccine which targets cells expressing IDO1 and PD-L1, compared to conventional checkpoint inhibitors and a second shares promising updates for IO170, which targets Transforming Growth Factor beta (TGF-β).
Neutral
GlobeNewsWire
2 months ago
IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting
• New non-clinical data strengthens evidence of contributions of IO102 and IO103 to tumor growth control through target specific T-cell activation, offering a distinct and complementary approach to checkpoint inhibitors • New preclinical data for IO170 add to growing body of evidence supporting the potential of immune-modulatory therapeutic cancer vaccines to treat a wide range of cancers NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that two abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 taking place April 25-30 in Chicago, Illinois. One of the posters will share insights, using non-clinical models, related to IO Biotech's lead investigational candidate, IO102-IO103, currently being evaluated in a pivotal Phase 3 trial in advanced melanoma.
Neutral
GlobeNewsWire
2 months ago
IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025
– Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines – NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company, has been named to Fast Company's prestigious list of the World's Most Innovative Companies of 2025. Fast Company recognizes 609 organizations across 58 sectors and regions.
Neutral
GlobeNewsWire
3 months ago
IO Biotech Reports 2024 Business Highlights
Preparations for submission of a Biologics License Application (BLA) for Cylembi o ® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023 ahead of plan with 407 patients.
Neutral
GlobeNewsWire
3 months ago
IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference
• Findings support the development of a novel peptide vaccine targeting the immunosuppressive effects of Transforming Growth Beta (TGF- β ) in solid tumors NEW YORK, Feb. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced details of its poster presentation at the American Association for Cancer Research (AACR)-IO conference taking place February 23-26, 2025, in Los Angeles, California. Poster Presentation Details Title: A TGF-β-directed peptide vaccine induces T cell activation & drives anti-tumor activity by modulating the architecture of the tumor microenvironment Poster number: B117 Presenter: Matteo Bocci, PhD, Senior Scientist Date and time: Tuesday, February 25, 2025, 1:45-4:00 PM PST Location: JW Marriott Los Angeles, Platinum Ballroom A-E Transforming Growth Factor Beta (TGF-β) is a key immune-suppressive factor in the tumor microenvironment (TME) of most solid tumors, often limiting the efficacy of various immune-oncology therapies.
Neutral
GlobeNewsWire
3 months ago
IO Biotech to Present at the 45th Annual Cowen Health Care Conference
Presentation will include an update on the development and launch preparations of Cylembio™ (imsapepimut and etimupepimut, adjuvanted) NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announced that Mai-Britt Zocca, PhD, President and CEO, will present a company overview at the 45th Annual Cowen Health Care Conference to be held March 3-5, 2025 in Boston, MA. Dr. Zocca, joined by Amy Sullivan, CFO, and Qasim Ahmad, MD, CMO, will also be hosting one-on-one investor meetings during the conference.
Charts implemented using Lightweight Charts™